A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some encouraging results. Researchers and doctors weigh in.

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

Clatterbridge was the first cancer research centre in the UK to give an injection of the Transgene experimental immunotherapy to a patient with ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

On August 22, 2024, Hamlet BioPharma announced the continuation of its series of digital investor meetings during the autumn.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.